Overview

A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs

Status:
NOT_YET_RECRUITING

Trial end date:
2029-01-04

Target enrollment:

Participant gender:

Summary

ANDROMEDA is a first-in-human, Phase I/II, open-label, multicenter study of AZD9750 in participants with metastatic prostate cancer. The trial evaluates safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy of AZD9750 as monotherapy and in combination with saruparib.

Phase:

PHASE1

Details

Lead Sponsor:

AstraZeneca

Treatments:

AZD5305